Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VB517 is a fully human mAb with low-picomolar affinity for c-KIT and has demonstrated potent suppression of human mast cell activation in preclinical models. ValenzaBio plans to initiate clinical studies of VB517 in 2023.
Lead Product(s): VB517
Therapeutic Area: Dermatology Product Name: VB517
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: ValenzaBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 15, 2022